AtaCor Medical develops extravascular cardiac pacing and defibrillation lead systems that eliminate the need for transvenous access, reducing the risks and complications associated with traditional methods. Their technology enables reliable temporary pacing and defibrillation while allowing for safe patient ambulation post-procedure.

Boomerang runs a clinical trial for ulcerative colitis that evaluates a non‑drug neurostimulation device aimed at reducing bowel urgency. Eligible patients complete an online survey to determine qualification, and participants receive medical support and possible travel stipends during the study. The company monetizes through research contracts and funding tied to the investigational device trial.

Cardiosense is developing a physiological waveform data platform that utilizes multi-sensor wearable devices and proprietary algorithms to detect early markers of cardiac disease. This technology enables continuous patient monitoring and personalized therapy, addressing the need for pre-symptomatic disease detection in cardiac care.

HistoSonics provides the Edison histotripsy system, a non‑invasive focused‑ultrasound platform that mechanically liquefies liver tumor tissue through controlled cavitation. Integrated real‑time ultrasound imaging guides beam placement and verifies treatment margins, enabling same‑day outpatient procedures with >90 % technical success and low major‑complication rates. The FDA‑cleared system is compatible with standard interventional radiology suites and targets unresectable liver lesions.

Iris Healthcare provides a technology-enabled Advance Care Planning solution that facilitates the creation of personalized advance directive documents through guided conversations with patients and their care teams. This approach addresses the complexities and stress of making informed healthcare decisions during serious illness by ensuring that individual goals and preferences are clearly documented and communicated to all relevant parties.

Myeloid Therapeutics develops mRNA-based immunotherapies that utilize in vivo mRNA programming and gene editing to enhance the immune response against cancer and autoimmune diseases. Their therapies aim to improve patient outcomes by harnessing the innate abilities of myeloid cells to target and eliminate malignant cells effectively.

Ribometrix develops small molecule drugs that target RNA biology to prevent the production of disease-causing proteins, addressing challenges in treating complex diseases such as cancer and autoimmune disorders. By binding directly to mRNAs or mRNA-binding proteins, Ribometrix's platform offers a novel approach to drug discovery that aims to manipulate key regulatory mechanisms in human health.

Standard Bariatrics develops the Titan SGS® stapler, a purpose-built device for sleeve gastrectomy that delivers a continuous staple line in a single firing, ensuring consistent and symmetrical pouch anatomy. This technology addresses variability in surgical outcomes by minimizing the number of staple cartridges used during the procedure, ultimately enhancing patient results.

StrideBio develops gene therapies using its proprietary STRIVETM Capsid Platform to create genetic medicines for patients with life-threatening diseases. The company focuses on delivering curative treatments that address the underlying genetic causes of severe conditions, improving patient outcomes and quality of life.

Synaptrix offers NOVABLOC, a drug-free solution for managing postoperative pain through targeted nerve block technology. This approach reduces reliance on opioids, minimizing the risk of addiction and enhancing patient recovery experiences.